Botox vs Jeuveau: Cost, Results & Is "Newtox" Worth It? (2026)

*FDA status: Botox (onabotulinumtoxinA) is FDA-approved for several cosmetic areas and many medical conditions. Jeuveau (prabotulinumtoxinA-xvfs) is FDA-approved only for moderate to severe glabellar (frown) lines. Using either brand on other facial areas is off-label. This guide is educational and is not medical advice.*

If you have researched wrinkle-relaxing injections, you have almost certainly seen Botox and its younger rival Jeuveau, marketed under the nickname Newtox. Both are purified forms of botulinum toxin type A, both temporarily relax the muscles that create expression lines, and both deliver comparable smoothing of the frown lines between the brows. The differences that actually matter are narrower than the marketing suggests: they come down to formulation, breadth of FDA approval, track record, and price. This guide walks through what the two products share, where they genuinely differ, who each one suits, how safe they are, and how to think about cost, so you can have an informed conversation with a qualified injector.

Botox and Jeuveau at a glance

Botox has been on the US market since 2002 for cosmetic use and is manufactured by AbbVie through its Allergan Aesthetics division. Jeuveau arrived in 2019, developed by Evolus, and was the first neurotoxin brought to the United States purely for aesthetics rather than adapted from medical use. Despite the age gap, head-to-head studies of the two products for frown lines show very similar results, with pivotal trials finding Jeuveau non-inferior to Botox. The table below summarizes the practical attributes patients ask about most. Treat it as a starting map, not a verdict: the single biggest driver of your result is the person holding the syringe, not the label on the vial.

What Botox and Jeuveau share

At the biological level these two products are close cousins. Both are botulinum toxin type A, the same protein family used across the entire neuromodulator category, and both work by the identical mechanism. Injected in tiny, precise amounts into a target muscle, the toxin blocks the release of acetylcholine, the chemical signal that tells the muscle to contract. With the muscle temporarily quieted, the overlying skin stops creasing and existing dynamic lines soften over the following days. Neither product fills or plumps anything, which is why toxins are used for movement lines rather than static volume loss, where dermal fillers are the appropriate tool instead.

They also share a similar clinical rhythm. Results are not instant: expect softening to begin within a few days and reach full effect around two weeks. The effect is temporary in both cases, generally lasting three to four months before the muscle gradually regains movement and a repeat appointment is needed. Both are prescription-only medicines that must be reconstituted and injected by a trained, licensed professional. And because they belong to the same drug class, their side-effect profiles, contraindications, and aftercare guidance are essentially the same, a point worth remembering whenever a clinic frames one product as dramatically safer or gentler than the other.

The treatment experience is nearly identical too. A typical appointment takes about ten to fifteen minutes, uses a very fine needle, and requires no downtime, so many patients return to normal activities the same day. Standard aftercare for both products is the same: stay upright for a few hours, avoid rubbing or massaging the area, and skip strenuous exercise, alcohol, and heat exposure for the first day. Both also reward consistency, since regular maintenance every few months tends to keep muscles relaxed and can, over time, soften how deeply lines etch into the skin at rest.

Key differences that actually matter

The most concrete difference is the active molecule and its accompanying formulation. Botox is onabotulinumtoxinA; Jeuveau is prabotulinumtoxinA-xvfs. They are manufactured by different companies using different proprietary processes, so units are brand-specific and are never mixed or converted casually. In practice, most injectors treat Botox and Jeuveau as roughly one to one, meaning a frown-line dose that would take about 20 units of Botox takes a similar number of Jeuveau units. That is not true of Dysport, whose units run on a completely different scale, which is why comparing Jeuveau to Botox is more straightforward than comparing either to Dysport.

Onset is the difference patients notice most. Some head-to-head data and many injectors report that Jeuveau can begin working marginally faster, occasionally within two to three days versus three to five for Botox, though individual response varies and the gap is small. Duration, by contrast, is broadly the same for both, at three to four months.

The larger practical gap is regulatory breadth. Botox carries a long list of FDA approvals: cosmetically for frown lines, crow's feet, and forehead lines, and medically for chronic migraine, excessive sweating, cervical dystonia, overactive bladder, and more. Jeuveau is approved for one thing only, moderate to severe glabellar frown lines, and has no medical indications at all. Using either product on the lower face, jaw, neck, or other regions is common in skilled practice but is, by definition, off-label for both brands.

Which is right for whom

For the frown lines directly between the eyebrows, the honest answer is that either product is an excellent choice and the results are hard to tell apart. If frown lines are your only concern and budget is a factor, Jeuveau is a reasonable, often slightly cheaper option that was purpose-built for exactly this use. Some patients also like the reported marginally faster onset when they are timing treatment before an event.

Botox becomes the clearer pick in a few situations. If you want to treat several areas in one visit, particularly the crow's feet or forehead lines that Botox is specifically approved for, staying with the product that carries those approvals is a sensible default. If you are treating a medical problem such as chronic migraine, jaw clenching, or excessive underarm sweating, Botox is the only one of the two with a meaningful track record and, for migraine and sweating, FDA approval; Jeuveau simply is not an option there. Patients who value the longest real-world safety record, now more than two decades for cosmetic Botox, may also prefer it on principle. None of this makes Jeuveau a lesser product for its intended job. It makes Botox the more versatile one across a wider range of goals.

Safety, side effects, and the Jeuveau ban question

Because they are the same class of medicine, Botox and Jeuveau carry the same core risks. The most common side effects are mild and temporary: redness, swelling, or bruising at the injection sites, headache, and, less often, a temporarily drooping eyelid or brow if the toxin migrates or is placed imperfectly. Serious problems are rare when a qualified professional injects appropriate doses, but all botulinum toxin products carry an FDA boxed warning about the theoretical risk of the toxin spreading beyond the treatment area, which can, in rare cases, cause swallowing or breathing difficulty. Both products should be avoided by people who are pregnant or breastfeeding, who have a neuromuscular disorder such as myasthenia gravis or ALS, who have an active infection at the injection site, or who are allergic to any component.

Patients often ask why Jeuveau was banned. It was not banned for any safety or health reason. In 2020 the US International Trade Commission ordered a temporary import ban after ruling that Jeuveau had been developed using manufacturing trade secrets misappropriated from a competitor, Medytox. In February 2021 Evolus, AbbVie, and Medytox settled the dispute, Evolus paid a settlement and licensed the technology, and the import ban was rescinded. Jeuveau has remained legally available and FDA-approved in the United States throughout. In other words, the story is a corporate legal matter about trade secrets, not a red flag about the product's safety or effectiveness.

Cost comparison: is "Newtox" actually cheaper?

Neuromodulators are usually priced one of two ways: per unit, or per treatment area. Jeuveau built its market position partly on value, and its per-unit price is often a little lower than Botox, which is how it earned the budget-friendly Newtox reputation. Because the two use a roughly one-to-one unit scale, a lower Jeuveau per-unit price can translate into a modestly cheaper frown-line treatment for a comparable result. Loyalty programs matter too: Botox is tied to Allergan's rewards program, while Jeuveau participates in Evolus Rewards, and the savings either program offers can outweigh the sticker gap on any given visit.

That said, no honest guide can quote you a firm price. Real cost depends on your region, the clinic's overhead and reputation, the injector's experience, how many units your muscles actually need, and current promotions. A frown-line treatment commonly falls within a broad range that varies widely by market, so any single dollar figure would be misleading. Chasing the lowest per-unit deal can also be a false economy if it means fewer units than you need or a less experienced injector. Compare the total cost for your goal, not the headline per-unit number, and weigh it against the skill of the person treating you.

How to choose between Botox and Jeuveau

Start with your goal, then choose the injector, and let the product follow. If you only want your frown lines softened and price matters, Jeuveau is a strong, purpose-built option. If you want multiple areas addressed, prefer an on-label approach for crow's feet or forehead lines, or are treating a medical condition, Botox is the more flexible choice. Beyond that, the brand is a smaller variable than the marketing implies.

What consistently separates a natural, refreshed result from a frozen or uneven one is the clinician's understanding of facial anatomy, dosing, and injection placement, not which vial they open. A well-trained injector will assess your muscle strength and facial movement, explain why they recommend a given product and dose, be candid about off-label areas, and set realistic expectations rather than promising a guaranteed look. When you consult, ask which product they recommend and why, how many units they plan to use, and what their plan is if you want an adjustment at your two-week follow-up. To take the next step, connect with a licensed, vetted injector near you who offers both Botox and Jeuveau and can tailor the choice to your face.